WHEAT RIDGE, CO--(Marketwire - December 19, 2008) - GeneThera, Inc. (PINKSHEETS: GTHR)
announced it will begin testing of raw and processed milk and dairy
products using its Real Time PCR test for Johne's disease through its Wheat
Ridge, CO laboratory.
GeneThera is set to begin offering its Johne's disease testing service as
soon as January of 2009 and says it will add testing of milk and other
dairy products due to the overwhelming evidence linking Johne's disease in
cattle to Irritable Bowel Syndrome (IBS) and Crohn's disease in humans.
According to GeneThera Chairman, Dr. Tony Milici, MD, PhD, "GeneThera
specializes in diagnostic assays and vaccines for what we call 'Crossover
Diseases.' These are diseases that are typically found in cattle, but
create a significant risk to humans that consume them. Some other examples
would be E. coli, and Bovine Spongiform Encephalopathy, otherwise known as
Mad Cow Disease. We feel that not enough is being done by the USDA to
properly protect the American consumer from these harmful pathogens."
According to the VA Medical Center in Bronx, NY, "... Although Crohn's
disease is considered to be autoimmune in origin; there is increasing
evidence that it may have an infectious cause. The most plausible candidate
is Mycobacterium avium subspecies paratuberculosis (MAP)."
In an article reviewed by About.com's Medical Review Board titled "Know
What's In Your Milk?," it is reported that the bacteria causing Johne's is
shed by the infected cow into her milk. The current pasteurization method
is based on High Temperature, Short Time (HTST). This means that the milk
is heated to 72 degrees Celsius (162 degrees F) for 15 seconds. The time
period of 15 seconds has been shown to be insufficient to kill all of the
paratuberculosis bacteria. As a result, paratuberculosis could live through
the pasteurization process and be in cartons of milk on grocery store
shelves. In fact, researchers found that up to 25% of milk on store shelves
in central and southern England contained paratuberculosis DNA.
A paper published by the Journal of Clinical Microbiology in December 2007
stated, "... Mucosal biopsy specimens from the ileum and the ascending and
descending colon were obtained from patients with irritable bowel syndrome
attending the University of Sassari, Sassari, Sardinia, Italy. Crohn's
disease and healthy control groups were also included. Mycobacterium avium
subsp. paratuberculosis was detected in 15 of 20 (75%) patients with
irritable bowel syndrome, 3 of 20 (15%) healthy controls, and 20 of 23
(87%) people with Crohn's disease." The paper concluded by saying,
"Mycobacterium avium subsp. paratuberculosis is a candidate pathogen in the
causation of a proportion of cases of irritable bowel syndrome as well as
in Crohn's disease."
Currently, there are no regulations requiring the disposal of milk found to
contain Mycobacterium Paratuberculosis. If milk tested on the farm or at a
processing plant is found to contain the bacteria, it is still processed
and delivered to stores.
The company states that its Real Time PCR test is much more accurate and
timely than what is commonly available today and results are typically
available within 24-48 hours of receipt of the samples.
ABOUT GENETHERA, INC.
GeneThera, Inc. is a molecular biotechnology company located in Wheat
Ridge, Colorado. The Company's proprietary diagnostic solution is based on
a genetic expression assay, GES™, a protocol designed to function on a
highly automated Fluorogenic PCR platform. This platform enables GeneThera
to offer tests that are presently not available from other technologies.
The GES is designed for a host of individual diseases, the current
priorities being Mad Cow disease, E. coli 0157:H7 and Johne's disease. For
more information, contact Dr. Tony Milici at 303-463-6371 or Al Goldsmith
of The Goldsmith Group LLC at 303-838-4370.
This press release contains forward-looking statements, which are made
pursuant to the Safe-Harbor provisions of the Private Securities Litigation
Reform Act of 1995. Words such as "intends," "believes," and similar
expressions reflecting something other than historical fact are intended to
identify forward-looking statements, but are not the exclusive means of
identifying such statements. These forward-looking statements involve a
number of risks and uncertainties, including the timely development and
market acceptance of products and technologies, the ability to secure
additional sources of finance, the ability to reduce operating expenses,
and other factors described in the Company's filings with the Securities
and Exchange Commission. The actual results that the Company achieves may
differ materially from any forward-looking statement due to such risks and
uncertainties. The Company undertakes no obligation to revise or update any
forward-looking statements in order to reflect events or circumstances that
may arise after the date of this release.